Pharma Pulse: FDA Greenlights Higher-Dose Wegovy with Pricing Commitments, and the State of the US Generics Market

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast in which we bring you the latest insights shaping patient access and healthcare innovation. I'm your host, and let's get into today's headlines.

• The FDA has fast-tracked approval for Wegovy HD, a 7.2 mg semaglutide injection for chronic weight management, under its new National Priority Voucher program. The approval was granted in just 54 days—significantly faster than the standard ten-month review—after the higher dose demonstrated a 20.7% mean weight loss in clinical trials. In exchange for the expedited review, the manufacturer agreed to specific pricing commitments for Medicare and Medicaid.
• In other news, a new report explores how "race-to-the-bottom" pricing may be straining the US generic drug market. With approximately 37% of approved generics between 2013 and 2024 failing to launch, some question if economic pressures are a primary driver of chronic shortages, sparking discussions regarding the need for PBM reforms and pricing floors.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access, visit pharmaceuticalcommerce.com. Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.